This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Cannigma has always taken a data-informed approach to content creation – though up until recently we’ve been primarily leaning on the existing peer-reviewed literature to guide our content. We need more data – human data – on specific applications for the plant – symptoms, use cases, conditions and patient types.
When you walk into a hardware store, pharmacy, or even a liquor store, if you don’t know exactly what product will meet your needs there’s someone educated enough to point you to the right product and the data to back up that recommendation, says Tyler Dautrich, COO of Releaf. Edited and mixed by Michael Schaeffer Omer-Man.
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. Media Contact: Will Johnson. 646) 421-9523. 201-465-8019.
Currently, with t he required certificate from a certified medical practitioner due to a qualifying condition, medical marijuana possession for patients is allowed in South Dakota. In the winter of 2023, according to South Dakota’s Data and Statistics report , close to 13,000 medical marijuana cardholders were registered.
(CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Using machine learning algorithms and qualified practitioner input, the company is leveraging that data to build tools that deliver digital diagnostic opinions.
By engaging individuals across various age groups and demographics, we gather insights into usage patterns, medical conditions, past substance experiences, and more. Understanding Gen Z Gen Z has been spotlighted in the media recently for a variety of reasons, one of which is that they are the largest consumers of media across any generation.
The Financial Times explains: “The excitement over cannabis in Colombia has reached fever pitch with some local media reports suggesting the country could supply two-fifths of the world’s marijuana and earn more from it than it does from coal or cut flowers. Strict Regulations. . Regulations will be difficult to meet and maintain.
Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.
A Pennsylvania bill meant to promote research into the therapeutic potential of psilocybin mushrooms for certain mental health conditions may be in jeopardy, with the sponsor saying that the chair of a key House committee is expressing reservations even after the legislation was amended in an effort to build support. The legislation from Rep.
In connection with the Closing, Harrison Baum , Chief Executive Officer of Daily High Club, has joined the High Tide team as Director of Digital Marketing to oversee all social media initiatives for High Tide globally. 1 As of June 21st, 2021, based on analytics data provided by Alexa Internet, Inc. ABOUT DHC SUPPLY LLC.
Spotlight PA sought that data to better understand the impact of the agency’s unusual and controversial decision to endorse cannabis as a treatment option for opioid use disorder. Qualifying conditions include anxiety disorders, severe chronic pain and epilepsy. It’s a very significant case,” Melewsky told Spotlight PA. “And
Notably, both the low and high ends of observed transaction data – $900 and $1,650 per kilogram – were up compared to May.”. Last year, farmers fought grasshopper infestations and it looks like this year conditions are ripe for an even bigger outbreak. The Hemp Benchmarks June report noted that the U.S.
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.
The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.”
The Company’s seven primary business segments include Retail, Agriculture, QSR & Hospitality, Media Technology & Gaming, Clean Energy and New Age Wellness. For media inquiries: Davis Richardson. The Company’s investment partnerships range from minority positions to large strategic holdings with active advisory mandates.
Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Watch how Supera-CBD works. “We
Ben Kaplan, CEO of Ehave, said, “We strongly believe there is a genetic predisposition to this condition and will be conducting a large-scale genetic analysis to isolate an individuals’ risk profile. If these visual disturbances occur frequently, you may have a condition called hallucinogen persisting perception disorder (HPPD).
Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. Forward-Looking Statement Disclaimer.
This hope comes from many individuals posting their stories (true or not) on social media. A comprehensive review published in JAMA Oncology examined clinical data and case reports on cannabis as an anticancer agent. Let me explain to you the interesting tale behind it and give you a detail of what defines it.
Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Some of the more interesting data on the relationship between opioids and medical marijuana for pain management comes from the field of orthopedic surgery. million to 11.4
All patients were carefully chosen from social media posts and Realm of Caring patient registries, with follow-up survey responses being collected from a subgroup of 190 participants. For example, rather than having researchers carry out a controlled investigation, each study subject provided self-reported data.
A recent study published in the Journal of the American Heart Association suggests a link between marijuana use and increased cardiovascular risks, sparking widespread media coverage with alarming headlines. This highlights the need for more rigorous, long-term studies to accurately assess the true impact of cannabis on heart health.
In an official statement to media sources, Dr. Drake said ; “We don’t find any evidence to support the theory that cannabis functions as a gateway drug… if anything, we find that recreational cannabis legalization decreases opioid-related emergency department visits.”
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Recent data suggest the US science knowledge is about the global average.
THC exposure for 60 minutes had only marginal effect on nociception under the conditions assessed. LJARI donated funds for some of the lobster purchases but was not directly involved in the design of the experiments, analysis and interpretation of data or the decision to submit the study for publication. Pain News Network reports.
Former President Bill Clinton has apparently been hearing a lot about the therapeutic potential of CBD products for pain management lately, and, according to a now-deleted media report, said at a recent conference appearance that broad interest in the topic should spur regulators to develop standards for the cannabinoid. Ganjapreneur report.
A Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation is expected to begin by the fourth quarter of 2021 with initial trial data expected in the first quarter of 2022. Media Contact: Will Johnson. About Oravax Medical. Oravax was established in March 2021 by Oramed Pharmaceuticals Inc.
Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.
Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. Researchers recruited 641 participants from Western Europe and America via Facebook groups, university mailing lists, and social media forums. The subjective nature of self-reported data can plague research.
Along with this transaction, our last two acquisitions have increased High Tide’s social media reach by leaps and bounds, giving us access to an invaluable potential customer base,” said Raj Grover, President and Chief Executive Officer of High Tide. Pursuant to the terms of the Transaction, High Tide USA Inc.,
The acquisition is expected to close in Q3 2021, subject to closing conditions and covenants customary for this type of transaction, including, without limitation, obtaining MED and local licensing approval. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. About Schwazze.
Clearly for the sake of our health and youth, we need more memes and less social media trolls. . About a year ago, data from the Strainprint app was used to analyze the impact of marijuana on depression, anxiety and stress. The data came from close to 12,000 entries (that’s a huge sample size!). So what does this all mean?
At this time the FDA has not evaluated what, if anything, these products are effective for and what appropriate doses might be, or whether there are counterindications for persons taking other drugs or having any other health conditions. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”.
It replaces traditional paper-based forms and manual data entry, improving efficiency, accuracy, and patient experience. Data Capture: This tool can capture patient information like demographic details, contact information, insurance details, medical history, allergies, and medication information.
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. Media Contact: Will Johnson. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. About FTSE Russell.
NEO lists companies and investment products seeking an internationally recognized stock exchange that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data. Media Laura Morarity. Additional Information and Where to Find It. laura.morarity@leafly.com 206-489-8427. Investors Peter Lee.
The CBD Insider’s 2021 US CBD Consumer Report provides some data around the CBD industry and what consumers want from CBD brands that can help savvy businesses stand out in the marketplace. Based on the data from the study, the breakdown of why U.S. A specific health condition or some other reason : 8.8%. Pets : 5.9%.
Forward-looking information is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances.
Delic expects to drive considerable patients to KWC through its media platform and build on the existing national leadership position already in place. With the addition of KWC, we can now reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments.
Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. SOURCE Khiron Life Sciences Corp.
The Arkansas medical marijuana program, established through the Arkansas Medical Marijuana Amendment in 2016, has paved the way for patients suffering from a variety of debilitating conditions to find relief and improved quality of life. Typically, medical marijuana cards need to be renewed annually.
He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. Anderson will be responsible for Anebulo’s global investor relations and public relations programs. Anebulo Pharmaceuticals, Inc.
At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.
Curaleaf CURLF, -7.27% is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” the FDA wrote. Mental conditions like anxiety, depression, and PTSD.”.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content